_id
690db598ccc777a4e85d0dcc
Ticker
BCAX
Name
Bicara Therapeutics Inc. Common Stock
Exchange
NASDAQ
Address
116 Huntington Avenue, Boston, MA, United States, 02116
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.bicara.com
Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Last Close
16.345
Volume
210069
Current Price
17.095
Change
0.345
Last Updated
2026-01-20T16:17:41.028Z
Image
data:image/webp;base64,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
Ipo Date
2024-09-13T00:00:00.000Z
Market Cap
917597696
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.977
Sentiment Sources
2
Rating
4.4286
Target Price
30.7778
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
40676000
Operating Income
-40676000
Interest Expense
-
Pretax Income
-36290000
Net Income
-36330000
Eps
-0.6658252795293237
Dividends Per Share
-
Shares Outstanding
54781950
Income Tax Expense
40000
EBITDA
-36234000
Operating Margin
-
Total Other Income Expense Net
4386000
Cash
171673000
Short Term Investments
118494000
Receivables
-
Inventories
-
Total Current Assets
297372000
Property Plant Equipment
2104000
Total Assets
424688000
Payables
3003000
Short Term Debt
1095000
Long Term Debt
-
Total Liabilities
21908000
Equity
402780000
Bs_currency_symbol
USD
Depreciation
24000
Change In Working Capital
3163000
Cash From Operations
-29248000
Capital Expenditures
42000
Cash From Investing
-236121000
Cash From Financing
436000
Net Change In Cash
-264933000
Cf_currency_symbol
USD
PE
3.1134
PB
2.3158281321813394
ROE
-9.019812304483837
ROA
-8.554515314772257
FCF
-29290000
Fcf Percent
-
Piotroski FScore
1
Health Score
43
Deep Value Investing Score
6
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
40676000
Quarters > 0 > income Statement > operating Income
-40676000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-36290000
Quarters > 0 > income Statement > net Income
-36330000
Quarters > 0 > income Statement > eps
-0.6658252795293237
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
54563864
Quarters > 0 > income Statement > income Tax Expense
40000
Quarters > 0 > income Statement > EBITDA
-36234000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
4386000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
171673000
Quarters > 0 > balance Sheet > short Term Investments
118494000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
297372000
Quarters > 0 > balance Sheet > property Plant Equipment
2104000
Quarters > 0 > balance Sheet > total Assets
424688000
Quarters > 0 > balance Sheet > payables
3003000
Quarters > 0 > balance Sheet > short Term Debt
1095000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
21908000
Quarters > 0 > balance Sheet > equity
402780000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-36330000
Quarters > 0 > cash Flow > depreciation
24000
Quarters > 0 > cash Flow > change In Working Capital
3163000
Quarters > 0 > cash Flow > cash From Operations
-29248000
Quarters > 0 > cash Flow > capital Expenditures
42000
Quarters > 0 > cash Flow > cash From Investing
-236121000
Quarters > 0 > cash Flow > cash From Financing
436000
Quarters > 0 > cash Flow > net Change In Cash
-264933000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.6658252795293237
Quarters > 0 > ratios > PB
2.3158281321813394
Quarters > 0 > ratios > ROE
-9.019812304483837
Quarters > 0 > ratios > ROA
-8.554515314772257
Quarters > 0 > ratios > FCF
-29290000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
43
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
19000
Quarters > 1 > income Statement > gross Profit
-19000
Quarters > 1 > income Statement > operating Expenses
32018000
Quarters > 1 > income Statement > operating Income
-32018000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-27336000
Quarters > 1 > income Statement > net Income
-27388000
Quarters > 1 > income Statement > eps
-0.5021706393727964
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
54539230
Quarters > 1 > income Statement > income Tax Expense
52000
Quarters > 1 > income Statement > EBITDA
-31999000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
4682000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
436606000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
444391000
Quarters > 1 > balance Sheet > property Plant Equipment
2354000
Quarters > 1 > balance Sheet > total Assets
453587000
Quarters > 1 > balance Sheet > payables
2911000
Quarters > 1 > balance Sheet > short Term Debt
1074000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
18391000
Quarters > 1 > balance Sheet > equity
435196000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-27388000
Quarters > 1 > cash Flow > depreciation
19000
Quarters > 1 > cash Flow > change In Working Capital
-1928000
Quarters > 1 > cash Flow > cash From Operations
-25594000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
135000
Quarters > 1 > cash Flow > net Change In Cash
-25459000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.5021706393727964
Quarters > 1 > ratios > PB
2.142363755296464
Quarters > 1 > ratios > ROE
-6.293256371841653
Quarters > 1 > ratios > ROA
-6.0380919206238275
Quarters > 1 > ratios > FCF
-25594000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
43
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
19000
Quarters > 2 > income Statement > gross Profit
-19000
Quarters > 2 > income Statement > operating Expenses
41788000
Quarters > 2 > income Statement > operating Income
-41788000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-36774000
Quarters > 2 > income Statement > net Income
-36846000
Quarters > 2 > income Statement > eps
-0.6766132573852733
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
54456515
Quarters > 2 > income Statement > income Tax Expense
72000
Quarters > 2 > income Statement > EBITDA
-41769000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
5014000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
462065000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
470754000
Quarters > 2 > balance Sheet > property Plant Equipment
688000
Quarters > 2 > balance Sheet > total Assets
478077000
Quarters > 2 > balance Sheet > payables
2740000
Quarters > 2 > balance Sheet > short Term Debt
591000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
19120000
Quarters > 2 > balance Sheet > equity
458957000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-36846000
Quarters > 2 > cash Flow > depreciation
19000
Quarters > 2 > cash Flow > change In Working Capital
5132000
Quarters > 2 > cash Flow > cash From Operations
-28106000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
460000
Quarters > 2 > cash Flow > net Change In Cash
-27646000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.6766132573852733
Quarters > 2 > ratios > PB
2.0283689407177574
Quarters > 2 > ratios > ROE
-8.028203077848252
Quarters > 2 > ratios > ROA
-7.707126676246713
Quarters > 2 > ratios > FCF
-28106000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
43
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
15000
Quarters > 3 > income Statement > gross Profit
-15000
Quarters > 3 > income Statement > operating Expenses
26637000
Quarters > 3 > income Statement > operating Income
-26637000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-20771000
Quarters > 3 > income Statement > net Income
-20957000
Quarters > 3 > income Statement > eps
-0.38495582284302543
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
54440013
Quarters > 3 > income Statement > income Tax Expense
186000
Quarters > 3 > income Statement > EBITDA
-26622000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
5866000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
489711000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
502533000
Quarters > 3 > balance Sheet > property Plant Equipment
845000
Quarters > 3 > balance Sheet > total Assets
569195000
Quarters > 3 > balance Sheet > payables
4508000
Quarters > 3 > balance Sheet > short Term Debt
607000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
77320000
Quarters > 3 > balance Sheet > equity
491875000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-20957000
Quarters > 3 > cash Flow > depreciation
15000
Quarters > 3 > cash Flow > change In Working Capital
-11995000
Quarters > 3 > cash Flow > cash From Operations
-30032000
Quarters > 3 > cash Flow > capital Expenditures
40000
Quarters > 3 > cash Flow > cash From Investing
-40000
Quarters > 3 > cash Flow > cash From Financing
-975000
Quarters > 3 > cash Flow > net Change In Cash
-31047000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.38495582284302543
Quarters > 3 > ratios > PB
1.8920498546073696
Quarters > 3 > ratios > ROE
-4.260635324015248
Quarters > 3 > ratios > ROA
-3.6818664956649303
Quarters > 3 > ratios > FCF
-30072000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
42
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
56000
Annuals > 0 > income Statement > gross Profit
-56000
Annuals > 0 > income Statement > operating Expenses
82389000
Annuals > 0 > income Statement > operating Income
-82389000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-67808000
Annuals > 0 > income Statement > net Income
-67995000
Annuals > 0 > income Statement > eps
-1.24933713657073
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
54424861
Annuals > 0 > income Statement > income Tax Expense
187000
Annuals > 0 > income Statement > EBITDA
-82333000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
14581000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
489711000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
502533000
Annuals > 0 > balance Sheet > property Plant Equipment
845000
Annuals > 0 > balance Sheet > total Assets
569195000
Annuals > 0 > balance Sheet > payables
4508000
Annuals > 0 > balance Sheet > short Term Debt
607000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
77320000
Annuals > 0 > balance Sheet > equity
491875000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-67995000
Annuals > 0 > cash Flow > depreciation
56000
Annuals > 0 > cash Flow > change In Working Capital
-14132000
Annuals > 0 > cash Flow > cash From Operations
-74751000
Annuals > 0 > cash Flow > capital Expenditures
71000
Annuals > 0 > cash Flow > cash From Investing
-9000
Annuals > 0 > cash Flow > cash From Financing
334031000
Annuals > 0 > cash Flow > net Change In Cash
259271000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-1.24933713657073
Annuals > 0 > ratios > PB
1.8915232504091486
Annuals > 0 > ratios > ROE
-13.823634053367218
Annuals > 0 > ratios > ROA
-11.945818216955525
Annuals > 0 > ratios > FCF
-74822000
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
35
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
19000
Annuals > 1 > income Statement > gross Profit
-19000
Annuals > 1 > income Statement > operating Expenses
39889000
Annuals > 1 > income Statement > operating Income
-39889000
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-51980000
Annuals > 1 > income Statement > net Income
-51985000
Annuals > 1 > income Statement > eps
-1.0043290377828449
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
51760925
Annuals > 1 > income Statement > income Tax Expense
5000
Annuals > 1 > income Statement > EBITDA
-39870000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-12091000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
230440000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
231073000
Annuals > 1 > balance Sheet > property Plant Equipment
815000
Annuals > 1 > balance Sheet > total Assets
233982000
Annuals > 1 > balance Sheet > payables
3186000
Annuals > 1 > balance Sheet > short Term Debt
285000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
15474000
Annuals > 1 > balance Sheet > equity
218508000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-51985000
Annuals > 1 > cash Flow > depreciation
19000
Annuals > 1 > cash Flow > change In Working Capital
-9624000
Annuals > 1 > cash Flow > cash From Operations
-45628000
Annuals > 1 > cash Flow > capital Expenditures
586000
Annuals > 1 > cash Flow > cash From Investing
-586000
Annuals > 1 > cash Flow > cash From Financing
272496000
Annuals > 1 > cash Flow > net Change In Cash
226282000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-1.0043290377828449
Annuals > 1 > ratios > PB
4.049522273211965
Annuals > 1 > ratios > ROE
-23.79089095136105
Annuals > 1 > ratios > ROA
-22.217521005889342
Annuals > 1 > ratios > FCF
-46214000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
29
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
10000
Annuals > 2 > income Statement > gross Profit
-10000
Annuals > 2 > income Statement > operating Expenses
37656000
Annuals > 2 > income Statement > operating Income
-37656000
Annuals > 2 > income Statement > interest Expense
112000
Annuals > 2 > income Statement > pretax Income
-37844000
Annuals > 2 > income Statement > net Income
-37845000
Annuals > 2 > income Statement > eps
-0.7311499939384777
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
51760925
Annuals > 2 > income Statement > income Tax Expense
1000
Annuals > 2 > income Statement > EBITDA
-37722000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-188000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
4158000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
4984000
Annuals > 2 > balance Sheet > property Plant Equipment
636000
Annuals > 2 > balance Sheet > total Assets
6703000
Annuals > 2 > balance Sheet > payables
5137000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
23981000
Annuals > 2 > balance Sheet > equity
-17278000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-37845000
Annuals > 2 > cash Flow > depreciation
10000
Annuals > 2 > cash Flow > change In Working Capital
4949000
Annuals > 2 > cash Flow > cash From Operations
-32076000
Annuals > 2 > cash Flow > capital Expenditures
192000
Annuals > 2 > cash Flow > cash From Investing
-192000
Annuals > 2 > cash Flow > cash From Financing
31695000
Annuals > 2 > cash Flow > net Change In Cash
-573000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.7311499939384777
Annuals > 2 > ratios > PB
-51.21269897412894
Annuals > 2 > ratios > ROE
219.03576802870703
Annuals > 2 > ratios > ROA
-564.5979412203491
Annuals > 2 > ratios > FCF
-32268000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
30
Valuation > metrics > PE
3.1134
Valuation > metrics > PB
2.3158281321813394
Valuation > final Score
100
Valuation > verdict
34.4% Undervalued
Profitability > metrics > ROE
-9.019812304483837
Profitability > metrics > ROA
-12.217021104878738
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.05439197576840955
Risk > metrics > Interest Coverage
-726.3571428571429
Risk > final Score
-2845
Risk > verdict
High
Liquidity > metrics > Current Ratio
72.56515373352855
Liquidity > metrics > Quick Ratio
72.56515373352855
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
33
Prev Risks > 1
27
Prev Risks > 2
42
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:27:56.920Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-26
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
0
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-11-10
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.67
Earnings History > 1 > eps Estimate
-0.5338
Earnings History > 1 > eps Difference
-0.1362
Earnings History > 1 > surprise Percent
-25.5152
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-08-12
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.5
Earnings History > 2 > eps Estimate
-0.5367
Earnings History > 2 > eps Difference
0.0367
Earnings History > 2 > surprise Percent
6.8381
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-05-13
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.68
Earnings History > 3 > eps Estimate
-0.398
Earnings History > 3 > eps Difference
-0.282
Earnings History > 3 > surprise Percent
-70.8543
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-27
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.39
Earnings History > 4 > eps Estimate
-0.2825
Earnings History > 4 > eps Difference
-0.1075
Earnings History > 4 > surprise Percent
-38.0531
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-12
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-1.6
Earnings History > 5 > eps Estimate
-0.5
Earnings History > 5 > eps Difference
-1.1
Earnings History > 5 > surprise Percent
-220
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-08-28
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-0.45
Earnings History > 6 > eps Estimate
-0.43
Earnings History > 6 > eps Difference
-0.02
Earnings History > 6 > surprise Percent
-4.6512
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AStocks To Watch: Bicara Therapeutics Sees Relative Strength Rating Rise To 81 Investor's Business Daily
Read more →Aug PostEarnings: Is BCAX part of any major index - July 2025 Update & Safe Capital Investment Plans bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$30.7778
Analyst Picks
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Bicara Therapeutics Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
0
Date
2025-09-30
EPS Actual
-0.67
EPS Estimate
-0.5338
EPS Difference
-0.1362
Surprise Percent
-25.5152%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.